The Role of Hypoxic Stop-Flow Perfusion and High Dose Chemotherapy in the Treatment of Regionally Advanced Colorectal Cancer

References

• Rich T, Gunderson LL, Lew R. Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 1983; 52: 1317–1329.
   PubMed Web of Science ®Google Scholar
• Philipshen SJ, Heilvweil M, Quan S. Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer 1984; 53: 1354–1363.
   PubMed Web of Science ®Google Scholar
• Rao AR, Kagan AR, Chan PM, et al. Patterns of recur-rence following curative resection alone for adenocarcinoma of the rectum and sigmoid colon. Cancer 1981; 48: 1492–1495.
   PubMed Web of Science ®Google Scholar
• Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 1979; 189: 496–502.
   PubMed Web of Science ®Google Scholar
• Cass AW, Million RR, Pfaff WW. Patterns of recur-rence following surgery alone for adenocarcinoma of the colon and rectum. Cancer 1976; 37: 2861–2865.
   PubMed Web of Science ®Google Scholar
• Stearns MW Jr. The choice among anterior resection, the pullthrough and abdominoperineal resection of the rec-tum. Cancer 1974; 34: 969–971.
   PubMedGoogle Scholar
• Moossa AR, Ree PC, Marks JE, et al. Factors influenc-ing local recurrence after abdominoperineal resection for can-cer of the rectum and rectosigmoid. Br J Surg 1975; 62: 727–730.
   PubMed Web of Science ®Google Scholar
• Slanetz CA, Herter FP, Grinnell RS. Anterior resection versus abdominoperineal resection for cancer of the rectum and rectosigmoid. Am J Surg 1972; 123: 110–117.
   PubMed Web of Science ®Google Scholar
• McDermott FT, Hughes ESR, Pihl E. Local recurrence after potentially curative resection for rectal cancer in a series of 1008 patients. Br J Cancer 1985; 72: 34–37.
   Web of Science ®Google Scholar
• Welch GP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 1979; 189: (4): 496–502.
   PubMed Web of Science ®Google Scholar
• Abrams MS, Lerner HJ. Survival of patients at Pennsylvania Hospital with hepatic metastases from carcino-ma of the colon and rectum. Dis Colon Rectum 1971; 14: 431.
   PubMed Web of Science ®Google Scholar
• Berge G, Ekelund C, Mullner BI. Carcinoma of the colon and rectum in a defined population. An epidemiologi-cal, clinical and postmortem investigation of colorectal carci-noma and coexisting benign polyps in Malmo, Sweden. Acta Chir Scand 1973; Suppl. 438-442.
   Google Scholar
• Mayo CW. Carcinoma of the colon and rectum. A study of metastasis and recurrence. Surg Gynecol Obstet 1942; 74: 83.
   Google Scholar
• Shindo K. Recurrence of carcinoma of the large intes-tine: a statistical review. Am J Proctol 1974; 25: 80.
   PubMedGoogle Scholar
• Willis RA. Spread of tumors in the human body. Butterworth and Co, London 1973: 417.
   Google Scholar
• August DA, Ottow RT, Sugarbaker PH. Clinical per-spective of human colorectal cancer metastasis. Cancer Metast 1984; 3: 303–324.
   PubMed Web of Science ®Google Scholar
• Patt YZ, Peters RE, Chuang VP, et al. Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-flu-orouracil and mitomycin. Cancer, 1985; 56: 2175-2180.
   Google Scholar
• Beyer JH, Berger H, Martin U. Intraarterial perfusion therapy with 5-fluorouracil in patients with metastatic col-orectal carcinoma and intractable pelvic pain. Rec Results Cancer Res 1983; 86: 33–36.
   PubMedGoogle Scholar
• Percivale P, Nobile MT, Vidili MG. Treatment of col-orectal cancer pelvic recurrences with hypogastric intra-arteri-al 5-fluorouracil by means of totally implantable port systems. Rev Cancer Treat 1990; 3: 143–146.
   Google Scholar
• Peters RE, Brunner H, Voghel D. Palliation of pelvic recurrences of colorectal cancer by intra-arterial chemothera-py. Proc Am Soc Clin Oncol 1982; 1: C–147.
   Google Scholar
• Estes NC, Morphis JC, Horseback NB et al. Intra-arte-rial chemotherapy and hyperthermia for pain control in patients with recurrent rectal cancer. Am J Surg 1986; 152: 597–601.
   Google Scholar
• James RD, O'Connel S, Burberry A. Prognostic factor in locally recurrent rectal cancer. Br J Surg 1983; 70: 496.
   Google Scholar
• Mohiuddin M, Kennedy N, Bowler R. Results of adju-vant radiation therapy in cancer of the rectum. Cancer 1985; 55: 350–352.
   PubMed Web of Science ®Google Scholar
• Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990; 77: 1241–1246.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Reinig JV, Hughes KS. Diagnosis of hepatic metastases. In: Rosenberg SA, ed.: Surgical treatment of metastatic cancer. Philadelphia: J. B. Lippincott 1987.
   Google Scholar
• Niederhuber JE, Ensminger W, Gyves J, et al. Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 1984; 53: 1336–1343.
   PubMed Web of Science ®Google Scholar
• Tagliacozzo S, Accordino M, Cangemi V, et al. Fattori prognostici nel trattamento chirrugico dei tumori primitivi e secondari del fegato. Archivio ed Atti della Societa' Italiana di Chirurgia 1996; 2: 556–578.
   Google Scholar
• Ballantyne GH, Quin J. Surgical treatment of liver metastase in patients with colorectal cancer. Cancer 1993; 71, Suppl: 4252-4266.
   Google Scholar
• Hughes KS, Simon R, Songhorabodi S et al. Resection of the liver for colorectal carcinoma metastases: a multi-insti-tutional study of patterns of recurrence. Surgery 1986; 100: 272–278.
   Google Scholar
• Scheele I, Stang R, Altendorf-Hoffman A, et al. Resection of colorectal liver metastases. World J Surg 1995; 19: 59–71.
   PubMed Web of Science ®Google Scholar
• Foster JH. Survival after liver resection for secondary tumors. Am J Surg 1978; 135: 389–394.
   PubMed Web of Science ®Google Scholar
• Fortner JG. Recurrence of colorectal cancer after hepatic resection. Am J Surg 1988; 155: 378–382.
   PubMed Web of Science ®Google Scholar
• Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 1987; 107: 459–465.
   PubMed Web of Science ®Google Scholar
• Hohn DC, Stagg RJ, Friedman MA, et al. A random-ized trial of continuous intravenous versus hepatic intra-arter-ial floxuridine in patients with colorectal cancer metastatic to the liver. The Northern California Oncology Group trial. J Clin Oncol 1989; 7: 1646–1654.
   PubMed Web of Science ®Google Scholar
• Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic con-tinuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Am Surg 1987; 206: 685–693.
   Google Scholar
• Martin JK, 0' Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metas-tases. Ann Surg 1990; 125: 1022–1027.
   Google Scholar
• Rougier P, Lapanhe A, Huguier M, et al. Hepatic arter-ial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long term results of a prospective randomized trial. J Clin Oncol 1992; 10: 1112–1115.
   PubMed Web of Science ®Google Scholar
• Tagughi T, Ogawa N, Bunke B, et al. The use of degradable starch microspheres (Spherex®) with intra-arterial chemoterapy for the treatment of primary and secondary liver tumors - results of a phase III clinical trial. Reg Cancer Treat 1992; 4: 161–164.
   Google Scholar
• Civalleri D, Pector JC, Hakansson L, et al. Treatment of patients with unresectable liver metastases from colorectal cancer by chemo-occlusion using degradable starch micros-pheres. Br J Surg (in press).
   Google Scholar
• Sasaki Y, Imaoka S, Masutani S, et al. Chemoembolization for liver metastasis from colorectal can-cer. Gan To Kagaku Ryoho 1990; 17: 1661–1664.
   PubMedGoogle Scholar
• Aigner KR. Filtration in high-dose regional chemother-apy. Contr Oncol 1988; 29: 271–280.
   Google Scholar
• Aigner KR, Kaevel K. Pelvic stop flow infusion (PSI) and hypoxic pelvic perfusion (HPP) with mitomycin and mel-phalan for recurrent rectal cancer. Reg Cancer Treat 1994; 7: 11–15.
   Google Scholar
• Aigner KR. Aortic stop flow infusion and hypoxic abdominal perfusion for dissemined bulky peritoneal carcino-matosis. Reg Cancer Treat. 1993; Suppl. 1: 3.
   Google Scholar
• Aigner K, Gailhofer S. Celiac axis infusion (MMC, CDDP, 5-FU) and aortic stop-flow infusion vs abdominal hypoxic perfusion (MMC) in UICC stage III/IV pancreatic cancer-48 patients. Reg Cancer Treat 1993; 6 (suppl. 1): 2.
   Google Scholar
• Aigner K, Kaevel K, Gailhofer S. Pelvic stop-flow infu-sion and hypoxic perfusion (PSI-HPP) for locally advanced bladder cancer. VII International Congress on Regional Cancer Treatment Wiesbaden 1995: 32.
   Google Scholar
• Aigner K, Gailhofer S. Celiac axis stop-flow infusion and hypoxic abdominal perfusion (MMC, melphalan) for pri-marily non resectable pancreatic cancer UICC stage III and IV - 70 patients. VII International Congress on Regional Cancer Treatment, Wiesbaden 1995: 49.
   Google Scholar
• Averbach AM, Sugarbaker PH. Advanced gastric can-cer: review of regional chemotherapy trials and treatment strategy using stop-flow infusion. Reg Cancer Treat 1995; 8: 67–76.
   Google Scholar
• Thompson JF, Liu M, Waugh RC, et al. A percuta-neous aortic “stop-flow” infusion technique for regional cyto-toxic therapy of the abdomen and pelvis. Reg Cancer Treat 1994; 7: 202–207.
   Google Scholar
• Klein ES, Berkenstadt H, Koller M, et al. Hemodynamic effects of aortic stop-flow and total abdominal ischemic perfusion. Reg Cancer Treat 1994; 2: 82–85.
   Google Scholar
• Cantore M, Fiorentini G, Poddie D, et al. Hypoxic abdominal perfusion (HAP): rationale and evaluation of a new technique. Reg Cancer Treat 1995; 8: 64–66.
   Google Scholar
• Bremner JCM, Stratford J, Bowler J, et al. Bioreductive drugs and the selective induction of tumour hypoxia. Br J Cancer 1990; 61: 717–721.
   PubMed Web of Science ®Google Scholar
• Sartorelli AC. Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res 1988; 48: 775–778.
   PubMedGoogle Scholar
• Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxy-genated and hypoxic tumor cells. Cancer Res 1981; 41: 73–81.
   PubMed Web of Science ®Google Scholar
• Moulder JE, Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987; 5: 313–341.
   PubMed Web of Science ®Google Scholar
• Rice GC, Bump EA, Shrieve DC et al. Quantitative analysis of cellular glutathione in Chinese hamster ovary cells by flow cytometry utilizing monochlorobimane: some applica-tions to radiation and drug resistance in vitro and in vivo. Cancer Res 1986; 46: 6105-6110.
   Google Scholar
• Kennedy KA. Hypoxic cells as specific drug targets for chemotherapy. Anti-cancer Drug Design 1987; 2: 181–194.
   PubMed Web of Science ®Google Scholar
• Bush RS, Jenkin RDT, Alit WEC et al. Definitive evi-dence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 1978; 37, suppl. III, 302.
   Google Scholar